Department for Children and Adolescents, Division for Stem Cell Transplantation, Immunology and Intensive Care Medicine, Goethe University, 60590 Frankfurt, Germany.
Research Group for Gene Modification in Stem Cells, Division of Veterinary Medicine, Paul-Ehrlich-Institute, 63225 Langen, Germany.
Int J Mol Sci. 2022 Mar 25;23(7):3578. doi: 10.3390/ijms23073578.
LFA-1 (Lymphocyte function-associated antigen-1) is a heterodimeric integrin (CD11a/CD18) present on the surface of all leukocytes; it is essential for leukocyte recruitment to the site of tissue inflammation, but also for other immunological processes such as T cell activation and formation of the immunological synapse. Absent or dysfunctional expression of LFA-1, caused by mutations in the (integrin subunit beta 2) gene, results in a rare immunodeficiency syndrome known as Leukocyte adhesion deficiency type I (LAD I). Patients suffering from severe LAD I present with recurrent infections of the skin and mucosa, as well as inflammatory symptoms complicating the clinical course of the disease before and after allogeneic hematopoietic stem cell transplantation (alloHSCT); alloHSCT is currently the only established curative treatment option. With this review, we aim to provide an overview of the intrinsic role of inflammation in LAD I.
LFA-1(淋巴细胞功能相关抗原-1)是一种存在于所有白细胞表面的异二聚体整合素(CD11a/CD18);它对于白细胞向组织炎症部位的募集至关重要,但对于其他免疫过程,如 T 细胞激活和免疫突触的形成也是必不可少的。由于(整合素亚基β2)基因突变导致 LFA-1 的缺失或功能障碍,会导致一种罕见的免疫缺陷综合征,称为白细胞黏附缺陷 I 型(LAD I)。患有严重 LAD I 的患者会反复出现皮肤和黏膜感染,以及异基因造血干细胞移植(alloHSCT)前后疾病的炎症症状,alloHSCT 是目前唯一已确立的治愈性治疗选择。通过本次综述,我们旨在概述炎症在 LAD I 中的内在作用。